Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics


Gracell Biotechnologies Inc. (GRCL): $5.14

0.15 (+3.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GRCL to Watchlist
Sign Up

Industry: Beverages


Ranked

of

in industry

GRCL Stock Price Chart Interactive Chart >

Price chart for GRCL

GRCL Price/Volume Stats

Current price $5.14 52-week high $15.00
Prev. close $4.99 52-week low $1.68
Day low $4.91 Volume 54,500
Day high $5.41 Avg. volume 232,545
50-day MA $3.13 Dividend yield N/A
200-day MA $6.03 Market Cap 347.49M

Gracell Biotechnologies Inc. (GRCL) Company Bio


Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.


GRCL Latest News Stream


Event/Time News Detail
Loading, please wait...

GRCL Latest Social Stream


Loading social stream, please wait...

View Full GRCL Social Stream

Latest GRCL News From Around the Web

Below are the latest news stories about Gracell Biotechnologies Inc that investors may wish to consider to help them evaluate GRCL as an investment opportunity.

Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced multiple advancements of its TruUCAR platform, the Company's proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered "off-the-shelf" as stand-alone therapy at lower cost and with greater conve

Yahoo | February 22, 2022

Week In Review: China's NMPA Approves Pfizer's Oral COVID-19 Therapy Paxlovid

Deals and Financings Shanghai AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma of Southern California. Today, AffaMed announced US approval to start clinical trials of the candidate, AM712, a dual inhibitor of vascular endothelial growth factor (VEGF)...

ChinaBio Today on Seeking Alpha | February 21, 2022

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has dosed multiple patients in a clinical trial evaluating GC012F, the Company's autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19 in B-cell non-Hodgkin's lymphoma (B-NHL). NHL is the fifth most common can

Yahoo | February 17, 2022

Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit

SUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Citi 2022 Immuno-Oncology Summit on February 16th. Dr. William Cao, Founder, Chairman and CEO of Gracell will participate in a fireside cha

Yahoo | February 3, 2022

Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference

SUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the B Riley Securities 2022 Virtual Oncology Conference from January 27th to 28th. The Gracell team is scheduled to have a presentation at 2:30

Yahoo | January 18, 2022

Read More 'GRCL' Stories Here

GRCL Price Returns

1-mo 63.17%
3-mo 111.52%
6-mo -9.03%
1-year -61.98%
3-year N/A
5-year N/A
YTD -14.90%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5155 seconds.